Angptl3 and Angptl4 differentially regulate circulating triglyceride levels during feeding and fasting states through the inhibition of lipoprotein lipase.
No takes yet. Share an insight, caveat, or question.
Preclinical Angptl3/4-LPL data require human validation; leaves open therapeutic translation in dyslipidemia.
Köster et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: